Lithium Ion

Lithium Ion

SCHEMBL1004907

CCN(C)c1nc2c(C(=O)[O-])cccc2o1.[Li+]

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR3A P46098 6/20 0.46
HCRTR1 O43613 1/20 0.37
HCRTR2 O43614 1/20 0.37
CMKLR1 Q99788 5/20 0.36
TOP2A P11388 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
KCNH2 Q12809 1/20 0.32
IDO1 P14902 1/20 0.32
MAOA P21397 1/20 0.32
MAOB P27338 1/20 0.32
PPARG P37231 1/20 0.32
PPARA Q07869 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium Ion SCHEMBL1004513 0.88 HTR3A (0.54) HTR3ACMKLR1TOP2ASMN1; SMN2ALDH1A1
SCHEMBL1004908 0.86 HTR3A (0.46) HTR3AHCRTR1HCRTR2CMKLR1TOP2A
SCHEMBL1005843 0.84 TOP2A (0.51) HTR3AHCRTR1HCRTR2TOP2ASMN1; SMN2
Lithium Ion SCHEMBL1003559 0.81 HTR3A (0.55) HTR3ACMKLR1TOP2APPARGPPARA
SCHEMBL24163185 0.76 HTR3A (0.48) HTR3ACMKLR1TOP2ASMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL1005853 0.74 CMKLR1 (0.41) HTR3AHCRTR1HCRTR2CMKLR1TOP2A
SCHEMBL1004991 0.74 HTR3A (0.56) HTR3AKCNH2
Hydrochloric Acid SCHEMBL1006568 0.73 HTR3A (0.55) HTR3AKCNH2
SCHEMBL1004992 0.73 HTR3A (0.86) HTR3AKCNH2
SCHEMBL1005419 0.73 HTR3A (0.53) HTR3ACMKLR1TOP2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7863271-B2 2-aminobenzoxazole carboxamides as 5HT3 modulators ALBANY MOLECULAR RESEARCH, INC. (US) 2011-01-04 US disclosed
EP-2061460-A2 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS Albany Molecular Research, Inc. (US) 2009-05-27 EP disclosed
US-20080255114-A1 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS AMR TECHNOLOGY, INC. (US) 2008-10-16 US disclosed
WO-2008019372-A2 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS ALBANY MOLECULAR RESEARCH, INC. (US) 2008-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255114-A1 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS HTR3E, HTR3C, HTR3A HTR3A 3/4885HCRTR1 456/4885HCRTR2 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.